Nothing Special   »   [go: up one dir, main page]

NO20072753L - 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer - Google Patents

3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer

Info

Publication number
NO20072753L
NO20072753L NO20072753A NO20072753A NO20072753L NO 20072753 L NO20072753 L NO 20072753L NO 20072753 A NO20072753 A NO 20072753A NO 20072753 A NO20072753 A NO 20072753A NO 20072753 L NO20072753 L NO 20072753L
Authority
NO
Norway
Prior art keywords
hydrazino
ethylidene
substituted heterocyclic
heterocyclic compounds
thrombopoietin receptor
Prior art date
Application number
NO20072753A
Other languages
English (en)
Inventor
Kazufumi Yanagihara
Yukihiro Shigeta
Katsuaki Miyaji
Satoshi Nakano
Shunsuke Iwamoto
Yutaka Hirokawa
Hirofumi Ota
Shingo Owada
Norihisa Ishiwata
Original Assignee
Nissan Chemical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nissan Chemical Ind Ltd filed Critical Nissan Chemical Ind Ltd
Publication of NO20072753L publication Critical patent/NO20072753L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30—Hetero atoms other than halogen
    • C07D333/32—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Forbindelser representert ved formel (1): hvor A, B, R1, L1, R2, L2, L3, Y, L4, R3 og X er det samme som definert i beskrivelsen, en tautomer, et promedikament eller et farmasøytisk akseptabelt salt av forbindelsen, eller et solvat derav. Nevnte forbindelser er anvendbare som trombopoietinreseptoraktivatorer.
NO20072753A 2004-12-08 2007-05-30 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer NO20072753L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004355195 2004-12-08
JP2005330891 2005-11-15
PCT/JP2005/022907 WO2006062240A1 (en) 2004-12-08 2005-12-07 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators

Publications (1)

Publication Number Publication Date
NO20072753L true NO20072753L (no) 2007-07-17

Family

ID=36021812

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072753A NO20072753L (no) 2004-12-08 2007-05-30 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer

Country Status (14)

Country Link
US (1) US8552031B2 (no)
EP (1) EP1819692A1 (no)
JP (1) JP4985402B2 (no)
KR (1) KR101215225B1 (no)
AU (1) AU2005312585B2 (no)
CA (1) CA2588979C (no)
HK (1) HK1115125A1 (no)
IL (1) IL183647A (no)
MX (1) MX2007006819A (no)
NO (1) NO20072753L (no)
NZ (1) NZ555466A (no)
RU (1) RU2395505C2 (no)
TW (1) TWI351954B (no)
WO (1) WO2006062240A1 (no)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA82695C2 (uk) * 2003-06-06 2008-05-12 Нисан Кемикал Индастриз, Лтд. Гетероароматичні сполуки як активатори рецептора тромбопоетину
JP4973192B2 (ja) * 2004-12-14 2012-07-11 日産化学工業株式会社 アミド化合物及びトロンボポエチンレセプター活性化剤
US7879318B2 (en) 2006-01-23 2011-02-01 Mcw Research Foundation, Inc. Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand
JP5157900B2 (ja) * 2006-06-07 2013-03-06 日産化学工業株式会社 含窒素ヘテロ環化合物及びトロンボポエチンレセプター活性化剤
EP2233561A4 (en) * 2007-12-05 2013-01-16 Nissan Chemical Ind Ltd METHOD FOR AMPLIFYING HEMATOPOIETIC STRAIN CELL USING HETEROCYCLIC COMPOUND
JP5573160B2 (ja) * 2007-12-05 2014-08-20 日産化学工業株式会社 ヘテロ環化合物による造血幹細胞の増幅方法
JP5573159B2 (ja) * 2007-12-05 2014-08-20 日産化学工業株式会社 ヘテロ環化合物による造血幹細胞の増幅方法
EP2492262B1 (en) * 2009-10-23 2016-04-20 Nissan Chemical Industries, Ltd. Fused heterocyclic compound and thrombopoietin receptor activator
EP2619216A4 (en) 2010-09-22 2014-04-02 Alios Biopharma Inc SUBSTITUTED NUCLEOTIDE ANALOG
US8980865B2 (en) 2011-12-22 2015-03-17 Alios Biopharma, Inc. Substituted nucleotide analogs
EP2828277A1 (en) 2012-03-21 2015-01-28 Vertex Pharmaceuticals Incorporated Solid forms of a thiophosphoramidate nucleotide prodrug
WO2013142157A1 (en) 2012-03-22 2013-09-26 Alios Biopharma, Inc. Pharmaceutical combinations comprising a thionucleotide analog

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU6046696A (en) 1995-06-07 1996-12-30 Glaxo Group Limited Peptides and compounds that bind to a receptor
US5869451A (en) 1995-06-07 1999-02-09 Glaxo Group Limited Peptides and compounds that bind to a receptor
PL188795B1 (pl) 1995-06-07 2005-04-29 Glaxo Group Ltd Związek wiążący się z receptorem trombopoetyny, kompozycja farmaceutyczna i zastosowanie związku wiążącego się z receptorem trombopoetyny
JPH1072492A (ja) 1996-09-02 1998-03-17 Hokuriku Seiyaku Co Ltd ペプチド化合物
JPH111477A (ja) 1997-06-12 1999-01-06 Hokuriku Seiyaku Co Ltd １，４−ベンゾジアゼピン誘導体及びその用途
AU9265698A (en) 1997-09-02 1999-03-22 Boehringer Mannheim Gmbh Mpl-receptor ligands, process for their preparation, medicaments containing themand their use for the treatment and prevention of thrombocytopaenia and anaemia
JPH11152276A (ja) 1997-11-20 1999-06-08 Hokuriku Seiyaku Co Ltd ベンゾジアゼピン誘導体
GC0000177A (en) 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
AU4692400A (en) 1999-05-03 2000-11-17 Smithkline Beecham Corporation Cxcr-4 receptor antagonists - thrombopoietin mimetics
WO2001007423A1 (fr) 1999-07-26 2001-02-01 Shionogi & Co., Ltd. Compositions medicamenteuses possedant une activite agoniste de la thrombopoietine
ATE315934T1 (de) 1999-09-10 2006-02-15 Smithkline Beecham Corp Thrombopoietin-mimetika
WO2001021180A1 (en) 1999-09-24 2001-03-29 Smithkline Beecham Corporation Thrombopoietin mimetics
JP2001097948A (ja) 1999-09-30 2001-04-10 Torii Yakuhin Kk トロンボポエチン受容体に親和性を有する化合物
AU1462201A (en) 1999-11-05 2001-06-06 Smithkline Beecham Corporation Semicarbazone derivatives and their use as thrombopoietin mimetics
WO2001039773A1 (en) 1999-12-06 2001-06-07 Smithkline Beecham Corporation Thrombopoietin mimetics
TWI284639B (en) 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
AU2002239718A1 (en) * 2000-12-19 2002-07-01 Ligand Pharmaceuticals Thrombopoietin mimetics
JP4145655B2 (ja) 2001-01-26 2008-09-03 塩野義製薬株式会社 トロンボポエチン受容体アゴニスト作用を有するハロゲン化合物
EP1361220A4 (en) 2001-01-26 2005-09-07 Shionogi & Co CYCLIC COMPOUNDS WITH THROMBOPOIETIN RECEPTAGONISM
WO2002062775A1 (fr) 2001-02-02 2002-08-15 Yamanouchi Pharmaceutical Co., Ltd. Dérivé de 2-acylaminothiazole ou son sel
EP1370252A4 (en) 2001-03-01 2006-04-05 Smithkline Beecham Corp Thrombopoietin mimetics
EP2314586B1 (en) 2002-01-18 2016-09-14 Astellas Pharma Inc. 2-Acylaminothiazole derivative or salt thereof
JP2003238565A (ja) 2002-02-19 2003-08-27 Japan Tobacco Inc 縮合環化合物及びそれら化合物を含んでなる血球増多薬
JP4412173B2 (ja) 2002-08-14 2010-02-10 日産化学工業株式会社 トロンボポエチンレセプター活性化剤ならびにそれらの製造方法
TWI324593B (en) 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
UA82695C2 (uk) * 2003-06-06 2008-05-12 Нисан Кемикал Индастриз, Лтд. Гетероароматичні сполуки як активатори рецептора тромбопоетину
JP4973192B2 (ja) * 2004-12-14 2012-07-11 日産化学工業株式会社 アミド化合物及びトロンボポエチンレセプター活性化剤

Also Published As

Publication number Publication date
KR101215225B1 (ko) 2012-12-26
MX2007006819A (es) 2007-07-24
EP1819692A1 (en) 2007-08-22
US20090281317A1 (en) 2009-11-12
RU2395505C2 (ru) 2010-07-27
HK1115125A1 (en) 2008-11-21
IL183647A (en) 2013-06-27
TW200626145A (en) 2006-08-01
NZ555466A (en) 2010-08-27
TWI351954B (en) 2011-11-11
CA2588979C (en) 2013-01-22
RU2007125639A (ru) 2009-01-20
WO2006062240A1 (en) 2006-06-15
KR20070104340A (ko) 2007-10-25
IL183647A0 (en) 2007-09-20
US8552031B2 (en) 2013-10-08
AU2005312585B2 (en) 2012-01-12
AU2005312585A1 (en) 2006-06-15
JP4985402B2 (ja) 2012-07-25
JP2008522956A (ja) 2008-07-03
CA2588979A1 (en) 2006-06-15

Similar Documents

Publication Publication Date Title
NO20072753L (no) 3-Etylidenhydrazinosubstituerte heterocykliske forbindelser som trombopoietinreseptoraktivatorer
NO20075734L (no) Tiofenforbindelser og trombopoietin reseptoractivatorer
NO20072344L (no) Trombineresptorantagonister.
TW200642689A (en) Immunosuppressive agent and anti-tumor agent comprising heterocyclic compound as active ingredient
DE602006011752D1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
NO20064077L (no) Kemokinreseptorantagonister
WO2007014054A3 (en) Benzenesulfonamide inhibitor of ccr2 chemokine receptor
NO20082389L (no) 2,3,4-trifenylimidazolinderivater som inhibitor av interaksjonen mellom P53- og MDM2-proteiner for anvendelse som antikreftmidler
WO2005103037A3 (de) Ausgewählte cgrp-antagonisten, verfahren zu deren herstellung sowie deren verwendung als arzneimittel
WO2005110410A3 (en) Kinase inhibitors as therapeutic agents
NO20054852L (no) GFAT inhibitorer
EA200801381A1 (ru) Производные пиримидина
ATE553106T1 (de) Heteroarylpyrrolopyridinone als kinaseinhibitoren
RS51444B (sr) JEDINJENJA KOJA SADRŽE LAKTAM I NJIHOVI DERIVATI KAO INHIBITORI FAKTORA Xa
NO20074763L (no) (1,5-difenyl-1H-pyrazol-3-yl)oksadiazolderivater, fremgangsmate ved fremstilling derav og anvendelse av samme i terapi
WO2006100082A3 (de) Substituierte oxindol-derivate, diese enthaltende arzneimittel und deren verwendung
WO2005105096A3 (en) Fused heterocyclic compounds
NO20074311L (no) Kinazolinderivat med tyrosinkinase-inhiberendeaktivitet
WO2007017728A3 (en) Novel heterocyclic compounds
MX2010001566A (es) Derivado de aminopirazolamida.
NO20063111L (no) Fremgangsmate for fremstilling av tiazolpyrimidiner
WO2004067703A3 (en) 5ht7 antagonists and inverse agonists
TW200724538A (en) Pyrazole compounds and thrombopoietin receptor activators
TW200626130A (en) 5-membered heterocycle derivatives
NO20062307L (no) Spirofuropyridinarylderivater

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application